These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 10522720)

  • 21. Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas.
    Izawa T; Obara T; Tanno S; Mizukami Y; Yanagawa N; Kohgo Y
    Cancer; 2001 Oct; 92(7):1807-17. PubMed ID: 11745253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status.
    Berger DH; Chang H; Wood M; Huang L; Heath CW; Lehman T; Ruggeri BA
    Cancer; 1999 Jan; 85(2):326-32. PubMed ID: 10023699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas.
    Hoshi T; Imai M; Ogawa K
    J Surg Oncol; 1994 Feb; 55(2):84-91. PubMed ID: 8121190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. K-ras gene mutations and loss of heterozygosity at the p53 gene locus relative to histological characteristics of mucin-producing tumors of the pancreas.
    Sakai Y; Yanagisawa A; Shimada M; Hidaka E; Seki M; Tada Y; Harada T; Saisho H; Kato Y
    Hum Pathol; 2000 Jul; 31(7):795-803. PubMed ID: 10923915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
    Yamaguchi K; Chijiiwa K; Noshiro H; Torata N; Kinoshita M; Tanaka M
    Hepatogastroenterology; 1999; 46(28):2575-81. PubMed ID: 10522044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
    Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
    Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucinous cystic neoplasms of the liver and pancreas: relationship between KRAS driver mutations and disease progression.
    Fujikura K; Akita M; Abe-Suzuki S; Itoh T; Zen Y
    Histopathology; 2017 Oct; 71(4):591-600. PubMed ID: 28570009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors.
    Kusaka T; Fukui H; Sano Y; Ueda Y; Chiba T; Fujimori T
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1151-7. PubMed ID: 11106095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region.
    Sturm PD; Hruban RH; Ramsoekh TB; Noorduyn LA; Tytgat GN; Gouma DJ; Offerhaus GJ
    J Pathol; 1998 Nov; 186(3):247-53. PubMed ID: 10211112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors.
    Kaino M; Kondoh S; Okita S; Hatano S; Shiraishi K; Kaino S; Okita K
    Pancreas; 1999 Apr; 18(3):294-9. PubMed ID: 10206488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras mutation in focal proliferative lesions of human pancreas.
    Terhune PG; Phifer DM; Tosteson TD; Longnecker DS
    Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):515-21. PubMed ID: 9641496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.
    Cerny WL; Mangold KA; Scarpelli DG
    Cancer Res; 1992 Aug; 52(16):4507-13. PubMed ID: 1643642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
    Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation.
    Matsubayashi H; Watanabe H; Nishikura K; Ajioka Y; Kijima H; Saito T
    Cancer; 1998 Feb; 82(4):651-60. PubMed ID: 9477096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
    Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
    Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status.
    Lüttges J; Neumann S; Jesenofsky R; Borries V; Löhr M; Klöppel G
    Pancreas; 2003 Oct; 27(3):e57-62. PubMed ID: 14508142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignancy risk factors and prognostic variables of pancreatic mucinous cystic neoplasms in Chinese patients.
    Xia Q; Li F; Min R; Sun S; Han YX; Feng ZZ; Li N
    World J Gastroenterol; 2023 May; 29(20):3119-3132. PubMed ID: 37346158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.